Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Fanconi anemia, complementation group S”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT00155896
What this trial is testing

Establishing the Incidences of BRCA1 and BRCA2 Mutation by Combining DHPLC and Direct Sequencing in Ovarian Cancer

Who this might be right for
Ovarian Cancer
National Taiwan University Hospital 100
Early research (Phase 1)Study completedNCT02418624
What this trial is testing

Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer

Who this might be right for
Breast CancerOvarian CancerAdvanced Cancer
The Netherlands Cancer Institute 25
Not applicableStudy completedNCT00165152
What this trial is testing

Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing

Who this might be right for
Breast CancerOvarian Cancer
Dana-Farber Cancer Institute 150
Not applicableActive Not RecruitingNCT07821229
What this trial is testing

Combination of Mitomycin and Carboplatin in Neoadjuvant Therapy in BRCA-associated Triple-negative Locally Advanced Breast Cancer

Who this might be right for
Breast Cancer (Early Breast Cancer)BRCA 1 Gene MutationBRCA 2 Gene Mutation
N.N. Petrov National Medical Research Center of Oncology 30
Large-scale testing (Phase 3)Ended earlyNCT01905592
What this trial is testing

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

Who this might be right for
Neoplasms, BreastCarcinoma of BreastHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast+3 more
Tesaro, Inc. 216
Early research (Phase 1)Study completedNCT03552471
What this trial is testing

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Who this might be right for
BRCA1 Gene MutationBRCA2 Gene MutationFolate Receptor Alpha Positive+7 more
Ohio State University Comprehensive Cancer Center 25
Early research (Phase 1)UnknownNCT01022333
What this trial is testing

The Potential for Oral Diindolylmethane (DIM) Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers

Who this might be right for
Breast Cancer
Women's College Hospital 300
Not applicableWithdrawnNCT02309632
What this trial is testing

Pancreatic Cancer Screening of High-Risk Individuals in Arkansas

Who this might be right for
Pancreatic NeoplasmsPeutz-Jegher's SyndromeBRCA1 Gene Mutation+5 more
University of Arkansas
Not applicableTemporarily pausedNCT02993068
What this trial is testing

Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

Who this might be right for
BARD1 Gene MutationBRCA1 Gene MutationBRCA2 Gene Mutation+12 more
M.D. Anderson Cancer Center 5,200
Early research (Phase 1)Study completedNCT03586661
What this trial is testing

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Deleterious BRCA1 Gene MutationDeleterious BRCA2 Gene MutationEndometrial Adenocarcinoma+8 more
M.D. Anderson Cancer Center 31
Testing effectiveness (Phase 2)Study completedNCT02282345
What this trial is testing

Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer

Who this might be right for
Breast AdenocarcinomaDeleterious BRCA1 Gene MutationDeleterious BRCA2 Gene Mutation+2 more
M.D. Anderson Cancer Center 36
Testing effectiveness (Phase 2)Looking for participantsNCT05485766
What this trial is testing

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast NeoplasmsTriple Negative Breast CancerBreast Neoplasms+5 more
Okayama University 23
Not applicableUnknownNCT02474264
What this trial is testing

The Link Between BRCA Mutation and Endothelial Function

Who this might be right for
BRCA1 Gene MutationBRCA2 Gene Mutation
Rabin Medical Center 82
Not applicableActive Not RecruitingNCT02321228
What this trial is testing

Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers

Who this might be right for
BRCA1 Gene MutationBRCA2 Gene MutationOvarian Cancer
University Medical Center Nijmegen 510
Early research (Phase 1)Study completedNCT01286987
What this trial is testing

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Who this might be right for
Advanced or Recurrent Solid TumorsBreast NeoplasmsOvarian Cancer, Epithelial+4 more
Pfizer 113
Not applicableStudy completedNCT05264532
What this trial is testing

Usefulness of Video-Based Intervention in Helping Participants Encourage Their Families to Get Tested for BRCA Gene Mutations

Who this might be right for
BRCA1 Gene MutationBRCA2 Gene Mutation
Ohio State University Comprehensive Cancer Center 58
Testing effectiveness (Phase 2)Study completedNCT02953457
What this trial is testing

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

Who this might be right for
BRCA1 Gene MutationBRCA2 Gene MutationOvarian Serous Adenocarcinoma+3 more
Roswell Park Cancer Institute 40
Large-scale testing (Phase 3)Study completedNCT01945775
What this trial is testing

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

Who this might be right for
Breast NeoplasmsBRCA 1 Gene MutationBRCA 2 Gene Mutation
Pfizer 431
Early research (Phase 1)Ended earlyNCT04182516
What this trial is testing

Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors

Who this might be right for
Advanced/Metastatic Solid Tumors
Nerviano Medical Sciences 52
Not applicableStudy completedNCT01948609
What this trial is testing

Prospective Research of Outcomes After Salpingo-oophorectomy

Who this might be right for
BRCA1 Gene MutationBRCA2 Gene Mutation
University of California, San Francisco 100
Next Page